Understanding genetic changes in neuroblastoma cells to pave the way for targeted treatments
Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities
Helping to develop research into antibody treatment
Investigation of ganglioside-specific receptor expression by tumour-infiltrating immune cells
Repurposing mebendazole and albendazole for acute myeloid leukaemia
Testing the use of mebendazole and albendazole for children with acute myeloid leukaemia, and investigating how the drugs work.
Developing a blood test to help identify high risk Wilms tumours
Circulating molecular biomarkers for earlier identification of high risk Wilms tumour
Can a carbohydrate restricted diet help treat childhood brain tumours?
In vitro evaluation of the potential of glucose restriction as an adjuvant therapy for paediatric brain tumours
Developing better and safer medicines for children with leukaemia
Screening for novel drug combinations in childhood B-cell acute lymphoblastic leukaemia
Improving treatment and reducing side effects for children with B-cell NHL
Identification of new drug targets to improve treatment options and reduce treatment-related toxicity for children diagnosed with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Developing new treatments for high-risk neuroblastoma
Pre-clinical efficacy and biomarker studies of ALK, MAPK and MDM2-p53 inhibitor combinations in neuroblastoma
Investigating a new way of delivery drugs to the site of childhood brain tumours
Brain distribution models to select polymer-delivered drugs for the treatment of childhood brain cancers